US · Healthcare · Biotechnology
EPS came in at -2.29 against a street estimate of -1.84 — a miss of 24.5%.
Analysts rate Revolution Medicines Inc a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $207.00.
| Fund | Stake |
|---|---|
| Farallon Capital Management, L.L.C. | 6.40% |
| BlackRock Inc | 5.27% |
| HHG PLC | 4.59% |
| Baker Bros Advisors LP | 4.49% |
| FMR Inc | 3.98% |
| Vanguard Capital Management, LLC | 3.93% |
| Nextech Invest, Ltd. | 3.58% |
| Vanguard Portfolio Management, LLC | 3.53% |
| Document | Date |
|---|---|
| Board / officer change · Q2 2026 | 2026-06-22 |
| Quarterly report · Q1 2026 | 2026-05-06 |
| Results announced · Q2 2026 | 2026-05-06 |
| Proxy statement · Q2 2026 | 2026-04-27 |
| Material agreement · Q2 2026 | 2026-04-17 |
| Company announcement · Q2 2026 | 2026-04-16 |
| Annual report FY2025 | 2026-02-25 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Revolution Medicines Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.